Moscow announces readiness of the Russian personal cancer vaccine to begin the treatment phase within 6 weeks
The director of the "Gamaliya" National Research Center for Epidemiology and Microbiology, Alexander Gintsburg, revealed that Russian scientists are ready to start treating patients using the first Russian mRNA cancer vaccine within the next six weeks.
The announcement came during a discussion session titled "The History of Russian Leadership in Medical Science and Technology," where Gintsburg stated that "the research team has already selected a group of patients and identified their individual genetic data," confirming that they are "ready to start treatment within six weeks through joint efforts."
The Russian scientific official explained that the experimental treatment will initially focus on skin cancer (melanoma) patients, using a vaccine developed at the Gamaliya Center based on innovative antigens. The highlight of the vaccine is that it is "personalized, meaning it is specifically designed for each individual patient."
Gintsburg pointed out the pivotal role of artificial intelligence in accelerating the process, stating: "It analyzes tumor indicators and creates a 'map' for the future drug, allowing specialists to prepare the vaccine in just one week."
With this step, Russia enters the advanced biotechnology race in the field of tumor treatment using mRNA technology, which promises to open new horizons for effective personalized therapies.
